Gefitinib for the Treatment of Non-Small-Cell Lung Cancer

Expert Opinion on Pharmacotherapy - United Kingdom
doi 10.1517/14656566.2010.481283
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa Healthcare

Related search

Successful Treatment of Non-Small Cell Lung Cancer With Gefitinib After Severe Erlotinib-Related Hepatotoxicity

Internal Medicine
Internal MedicineMedicine
2012English

ILD During Erlotinib and Gefitinib Treatment in Japanese Patients With Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2010English

Management of Patients With Advanced Non-Small Cell Lung Cancer: Role of Gefitinib

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2010English

ERK Inhibition Represses Gefitinib Resistance in Non-Small Cell Lung Cancer Cells

Oncotarget
Oncology
2018English

Inhibition of SREBP Increases Gefitinib Sensitivity in Non-Small Cell Lung Cancer Cells

Oncotarget
Oncology
2016English

First-Line Single Agent Treatment With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2010English

Gefitinib in Pretreated Advanced Non-Small Cell Lung Cancer (Nsclc): Analysis of Efficacy

Research in Oncology
2009English

On the Pharmacogenetics of Non-Small Cell Lung Cancer Treatment

Expert Opinion on Drug Metabolism and Toxicology
MedicineToxicologyPharmacology
2016English

Challenges in Bevacizumab and Gefitinib Combination Therapy for Patients With Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy